CDH13 and sarcoma: The results reveal hypermethylation of the CDH13 promoter in cancers such as kidney renal papillary cell carcinoma (KIRP), pancreatic cancer, uveal melanoma (UM) and acute myeloid leukemia (AML) and sarcoma (Fig. 1D).